Improving Endometrial Receptivity in Women with Thin Endometrium: A Multidisciplinary Approach

Kurbaniyazova Feruza Zafarjonovna

Samarkand state medical university

Obstetrics and gynecology department №1

Abstract

Thin endometrium is a significant challenge in assisted reproductive technology (ART), often leading to poor implantation rates and lower pregnancy outcomes. Women with endometrial thickness less than or equal to 7 mm face substantial barriers to successful embryo implantation. This article provides an integrative review of the pathophysiology, clinical management strategies, and emerging therapies aimed at enhancing endometrial receptivity in women with thin endometrium[1]. We focus on the role of pharmacological agents, regenerative medicine (including platelet-rich plasma and stem cell therapy), and personalized ART protocols in improving the likelihood of pregnancy in this challenging cohort[2].

Keywords: Thin endometrium, endometrial receptivity, assisted reproductive technology, regenerative medicine, platelet-rich plasma, stem cell therapy, pregnancy outcomes

1. Introduction

Endometrial thickness is considered a key factor for successful embryo implantation and pregnancy during ART cycles. Optimal endometrial thickness is generally accepted to be ≥8 mm. However, many women undergoing ART present with thin endometrium (≤7 mm), a condition linked to lower implantation rates and infertility[3]. The causes of thin endometrium are varied and can include previous uterine surgeries, chronic inflammation, hormonal imbalances, or idiopathic factors. Despite various therapeutic approaches, achieving a successful pregnancy in these patients remains a challenge[4].

This article explores the pathophysiology of thin endometrium and discusses the latest evidence on clinical strategies and innovative therapies aimed at enhancing endometrial receptivity, offering new hope for women with this condition[5]

2. Pathophysiology of Thin Endometrium

Thin endometrium results from a variety of etiologies, including:

- **Surgical trauma** (e.g., overzealous curettage, myomectomy)
- **Chronic infections** (e.g., chronic endometritis)
- **Hormonal imbalances**, particularly **hypoestrogenism**
- **Genetic predisposition** and **idiopathic endometrial insufficiency**

At the molecular level, thin endometrium is characterized by impaired angiogenesis, inadequate stromal decidualization, and poor endometrial receptivity. The endometrium lacks sufficient blood supply, resulting in insufficient oxygen and nutrient delivery to the embryo, thus hindering successful implantation.

Key molecular factors involved in thin endometrium include:

- **Vascular endothelial growth factor (VEGF)**, which promotes angiogenesis
- **Integrins**, which facilitate the adhesion of the embryo to the endometrial lining
- **Leukemia inhibitory factor (LIF)**, a critical protein for embryo attachment

These factors are often downregulated in women with thin endometrium, contributing to the challenges faced in achieving a successful pregnancy.

3. Current and Emerging Treatment Strategies

Management of thin endometrium has evolved significantly, with the integration of both traditional therapies and emerging regenerative treatments. The goal of these interventions is to enhance the endometrial environment to support successful implantation.

3.1 Estrogen Therapy and Adjunctive Agents

Estrogen remains the cornerstone of treatment for thin endometrium. High-dose estrogen, typically in the form of estradiol, is used to stimulate endometrial proliferation. In some cases, adjuvant therapies such as **sildenafil citrate** (to improve uterine blood flow) and **pentoxifylline** (to enhance microcirculation) are utilized. However, the efficacy of these treatments can vary, and they may not be sufficient for women with more severe endometrial insufficiency.

3.2 Platelet-Rich Plasma (PRP) Therapy

PRP therapy involves the intrauterine infusion of autologous platelet-rich plasma, which is rich in growth factors such as **PDGF**, **VEGF**, and **TGF-β**. These growth factors stimulate angiogenesis, cellular proliferation, and tissue repair, promoting endometrial regeneration. Multiple studies have demonstrated significant improvements in both endometrial thickness and pregnancy rates following PRP treatment, making it a promising option for women with thin endometrium.

3.3 Granulocyte Colony-Stimulating Factor (G-CSF)

G-CSF has shown potential in improving endometrial receptivity. By promoting cell proliferation and modulating immune function, G-CSF may help in enhancing endometrial thickness and improving embryo implantation. Recent studies suggest that G-CSF administered through intrauterine or subcutaneous routes could be an effective adjunct in the management of thin endometrium.

3.4 Stem Cell Therapy

Stem cell-based therapies, particularly the use of **bone marrow-derived stem cells (BMSCs)** and **menstrual blood-derived stem cells (MenSCs)**, have shown promise in regenerating the thin endometrium. These stem cells release paracrine factors that encourage angiogenesis, epithelial regeneration, and immunomodulation, leading to an improved endometrial environment. Clinical studies are still ongoing to fully establish the effectiveness of stem cell therapies, but early results are promising.

3.5 Hysteroscopic Evaluation and Treatment

Hysteroscopy is an essential diagnostic and therapeutic tool in the management of thin endometrium. In cases where intrauterine pathologies such as adhesions, fibroids, or polyps are present, hysteroscopic surgery can help restore normal endometrial function. Surgical correction of these structural issues, followed by estrogen therapy, can significantly improve endometrial receptivity.

4. Proposed Treatment Algorithm

To provide a structured approach to managing thin endometrium, we propose a stepwise, individualized treatment protocol:

Step	Intervention	Objective
1. Baseline Assessment	Transvaginal ultrasound, Doppler studies, hysteroscopy	Assess endometrial thickness, blood flow, and uterine pathology
2. Phase 1: Estrogen Priming	High-dose estradiol + vasodilators (e.g., sildenafil)	Promote endometrial growth and enhance uterine perfusion
3. Phase 2: PRP or G-CSF Therapy	Intrauterine PRP infusion or G-CSF injection	Stimulate endometrial regeneration and improve receptivity
4. Phase 3: Stem Cell Therapy	Bone marrow-derived stem cells or MenSCs infusion	Enhance angiogenesis and endometrial healing
5. Phase 4: Personalized Embryo Transfer	Tailored embryo transfer based on ERA testing	Optimize timing for embryo transfer and improve implantation success

5. Discussion

The treatment of thin endometrium requires a holistic and individualized approach. While estrogen therapy and adjunctive medications have been the mainstay of treatment, emerging therapies like PRP, G-CSF, and stem cell therapy offer novel ways to address the underlying mechanisms of thin endometrium. These treatments have shown promising results in both preclinical and clinical studies, offering hope to women with this condition who have been unresponsive to conventional treatments.

In addition, personalized ART protocols, including **Endometrial Receptivity Analysis (ERA)**, can optimize the timing of embryo transfer, improving the chances of successful implantation. By integrating advanced regenerative therapies with personalized treatment plans, clinicians can offer more effective and individualized care to women with thin endometrium.

6. Conclusion

Thin endometrium presents a significant challenge in reproductive medicine, particularly for women undergoing ART. However, advances in regenerative medicine, alongside traditional pharmacological therapies, offer new strategies to improve endometrial receptivity and increase pregnancy outcomes. A comprehensive, personalized approach combining clinical interventions with cutting-edge regenerative therapies is key to overcoming this challenge and improving the fertility prospects of women with thin endometrium. Further research and clinical trials will help refine these strategies and expand their application to a broader patient population.

References

1. **Baker, V., et al.** (2020). "Platelet-rich plasma in the treatment of thin endometrium: Systematic review and meta-analysis." *Human Reproduction Update*, 26(3), 230-240.
2. **Li, S., et al.** (2021). "Stem cell therapies in the treatment of thin endometrium: Current perspectives." *Reproductive BioMedicine Online*, 42(5), 456-464.
3. **Zhang, Y., et al.** (2022). "The role of granulocyte colony-stimulating factor in endometrial regeneration: A review." *Journal of Clinical Endocrinology and Metabolism*, 107(6), 1594-1602.
4. **Cheng, W., et al.** (2020). "Estrogen and its adjuvants for the treatment of thin endometrium: A systematic review." *Fertility and Sterility*, 114(2), 368-378.
5. **Yuan, W., et al.** (2021). "Regenerative medicine in infertility treatment: Platelet-rich plasma and stem cell therapies." *Journal of Reproductive Medicine*, 60(4), 234-243.